{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T17:32:07Z","timestamp":1771263127209,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"4","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1007\/s40121-016-0132-z","type":"journal-article","created":{"date-parts":[[2016,9,27]],"date-time":"2016-09-27T10:21:06Z","timestamp":1474971666000},"page":"473-489","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Atazanavir and Cardiovascular Risk Among Human Immunodeficiency Virus-Infected Patients: A Systematic Review"],"prefix":"10.1007","volume":"5","author":[{"given":"Dominic","family":"Chow","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecilia","family":"Shikuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corey","family":"Ritchings","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muxing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Rosenblatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,9,27]]},"reference":[{"issue":"9635","key":"132_CR1","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0140-6736(08)61113-7","volume":"372","author":"Antiretroviral Therapy Cohort Collaboration","year":"2008","unstructured":"Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008;372(9635):293\u20139.","journal-title":"Lancet"},{"key":"132_CR2","doi-asserted-by":"publisher","unstructured":"Hanna DB, Ramaswamy C, Kaplan RC, et al. Trends in cardiovascular disease mortality among persons with HIV in New York City, 2001\u20132012. Clin Infect Dis. 2016. doi: 10.1093\/cid\/ciw470 .","DOI":"10.1093\/cid\/ciw470"},{"issue":"2","key":"132_CR3","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1161\/CIRCULATIONAHA.107.189624","volume":"118","author":"JS Currier","year":"2008","unstructured":"Currier JS, Lundgren JD, Carr A, et al. Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation. 2008;118(2):e29\u201335.","journal-title":"Circulation"},{"issue":"1","key":"132_CR4","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1093\/cid\/cit196","volume":"57","author":"M Rotger","year":"2013","unstructured":"Rotger M, Glass TR, Junier T, et al. Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons. Clin Infect Dis. 2013;57(1):112\u201321.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"132_CR5","doi-asserted-by":"crossref","first-page":"e44454","DOI":"10.1371\/journal.pone.0044454","volume":"7","author":"DA Duprez","year":"2012","unstructured":"Duprez DA, Neuhaus J, Kuller LH, et al. Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS One. 2012;7(9):e44454.","journal-title":"PLoS One"},{"issue":"1","key":"132_CR6","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1056\/NEJMra041811","volume":"352","author":"S Grinspoon","year":"2005","unstructured":"Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med. 2005;352(1):48\u201362.","journal-title":"N Engl J Med"},{"issue":"2","key":"132_CR7","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1177\/135965350801300215","volume":"13","author":"AN Phillips","year":"2008","unstructured":"Phillips AN, Carr A, Neuhaus J, et al. Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. Antivir Ther. 2008;13(2):177\u201387.","journal-title":"Antivir Ther"},{"issue":"3","key":"132_CR8","doi-asserted-by":"crossref","first-page":"e59551","DOI":"10.1371\/journal.pone.0059551","volume":"8","author":"C Bavinger","year":"2013","unstructured":"Bavinger C, Bendavid E, Niehaus K, et al. Risk of cardiovascular disease from antiretroviral therapy for HIV: a systematic review. PLoS One. 2013;8(3):e59551.","journal-title":"PLoS One"},{"issue":"17","key":"132_CR9","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa062744","volume":"356","author":"N Friis-Moller","year":"2007","unstructured":"Friis-Moller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356(17):1723\u201335.","journal-title":"N Engl J Med"},{"issue":"3","key":"132_CR10","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1086\/649897","volume":"201","author":"SW Worm","year":"2010","unstructured":"Worm SW, Sabin C, Weber R, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis. 2010;201(3):318\u201330.","journal-title":"J Infect Dis"},{"issue":"9","key":"132_CR11","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1093\/jac\/dkq231","volume":"65","author":"D Carey","year":"2010","unstructured":"Carey D, Amin J, Boyd M, Petoumenos K, Emery S. Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir\/ritonavir: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2010;65(9):1878\u201388.","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"132_CR12","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s00592-014-0708-6","volume":"52","author":"J Milian","year":"2015","unstructured":"Milian J, Goldfine AB, Zuflacht JP, Parmer C, Beckman JA. Atazanavir improves cardiometabolic measures but not vascular function in patients with long-standing type 1 diabetes mellitus. Acta Diabetol. 2015;52(4):709\u201315.","journal-title":"Acta Diabetol"},{"issue":"2","key":"132_CR13","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1161\/ATVBAHA.110.211789","volume":"31","author":"D Dekker","year":"2011","unstructured":"Dekker D, Dorresteijn MJ, Pijnenburg M, et al. The bilirubin-increasing drug atazanavir improves endothelial function in patients with type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol. 2011;31(2):458\u201363.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"14","key":"132_CR14","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1097\/QAD.0000000000000762","volume":"29","author":"JH Stein","year":"2015","unstructured":"Stein JH, Ribaudo HJ, Hodis HN, et al. A prospective, randomized clinical trial of antiretroviral therapies on carotid wall thickness. AIDS. 2015;29(14):1775\u201383.","journal-title":"AIDS"},{"issue":"11","key":"132_CR15","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1093\/clinchem\/46.11.1723","volume":"46","author":"M Mayer","year":"2000","unstructured":"Mayer M. Association of serum bilirubin concentration with risk of coronary artery disease. Clin Chem. 2000;46(11):1723\u20137.","journal-title":"Clin Chem"},{"issue":"7","key":"132_CR16","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/M14-1084","volume":"161","author":"JL Lennox","year":"2014","unstructured":"Lennox JL, Landovitz RJ, Ribaudo HJ, et al. Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann Intern Med. 2014;161(7):461\u201371.","journal-title":"Ann Intern Med"},{"issue":"1","key":"132_CR17","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1056\/NEJM199901073400103","volume":"340","author":"DH O\u2019Leary","year":"1999","unstructured":"O\u2019Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson Jr SK. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med. 1999;340(1):14\u201322.","journal-title":"N Engl J Med"},{"issue":"4","key":"132_CR18","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.ahj.2010.06.029","volume":"160","author":"ZD Goldberger","year":"2010","unstructured":"Goldberger ZD, Valle JA, Dandekar VK, Chan PS, Ko DT, Nallamothu BK. Are changes in carotid intima-media thickness related to risk of nonfatal myocardial infarction? A critical review and meta-regression analysis. Am Heart J. 2010;160(4):701\u201314.","journal-title":"Am Heart J"},{"issue":"1","key":"132_CR19","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.atherosclerosis.2006.05.005","volume":"192","author":"D Shimbo","year":"2007","unstructured":"Shimbo D, Grahame-Clarke C, Miyake Y, et al. The association between endothelial dysfunction and cardiovascular outcomes in a population-based multi-ethnic cohort. Atherosclerosis. 2007;192(1):197\u2013203.","journal-title":"Atherosclerosis"},{"issue":"3","key":"132_CR20","first-page":"183","volume":"1","author":"HA Hadi","year":"2005","unstructured":"Hadi HA, Carr CS, Al Suwaidi J. Endothelial dysfunction: cardiovascular risk factors, therapy, and outcome. Vasc Health Risk Manag. 2005;1(3):183\u201398.","journal-title":"Vasc Health Risk Manag"},{"key":"132_CR21","unstructured":"National Institutes of Clinical Excellence. The guidelines manual 2012. Appendix C: Methodology checklist: randomised controlled trials. Available from https:\/\/www.nice.org.uk\/process\/pmg6\/resources\/the-guidelines-manual-appendices-bi-1967364\/chapter\/2-appendix-c-methodology-checklist-randomised-controlled-trials . Accessed 18 August 2016."},{"issue":"6","key":"132_CR22","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1136\/jech.52.6.377","volume":"52","author":"SH Downs","year":"1998","unstructured":"Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Commun Health. 1998;52(6):377\u201384.","journal-title":"J Epidemiol Commun Health"},{"issue":"6","key":"132_CR23","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1097\/QAD.0b013e3283352ed5","volume":"24","author":"RL Murphy","year":"2010","unstructured":"Murphy RL, Berzins B, Zala C, et al. Change to atazanavir\/ritonavir treatment improves lipids but not endothelial function in patients on stable antiretroviral therapy. AIDS. 2010;24(6):885\u201390.","journal-title":"AIDS"},{"issue":"6","key":"132_CR24","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/j.1468-1293.2011.00917.x","volume":"12","author":"D Podzamczer","year":"2011","unstructured":"Podzamczer D, Andrade-Villanueva J, Clotet B, et al. Lipid profiles for nevirapine vs. atazanavir\/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48\u00a0weeks, in treatment-naive HIV-1-infected patients (the ARTEN study). HIV Med. 2011;12(6):374\u201382.","journal-title":"HIV Med"},{"issue":"13","key":"132_CR25","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1097\/QAD.0b013e32833bee1b","volume":"24","author":"KE Squires","year":"2010","unstructured":"Squires KE, Young B, Dejesus E, et al. Similar efficacy and tolerability of atazanavir compared with atazanavir\/ritonavir, each with abacavir\/lamivudine after initial suppression with abacavir\/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients. AIDS. 2010;24(13):2019\u201327.","journal-title":"AIDS"},{"issue":"8","key":"132_CR26","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1093\/infdis\/jir505","volume":"204","author":"PE Sax","year":"2011","unstructured":"Sax PE, Tierney C, Collier AC, et al. Abacavir\/lamivudine versus tenofovir DF\/emtricitabine as part of combination regimens for initial treatment of HIV: final results. J Infect Dis. 2011;204(8):1191\u2013201.","journal-title":"J Infect Dis"},{"issue":"5","key":"132_CR27","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1136\/hrt.2007.137646","volume":"95","author":"AJ Flammer","year":"2009","unstructured":"Flammer AJ, Vo NT, Ledergerber B, et al. Effect of atazanavir versus other protease inhibitor-containing antiretroviral therapy on endothelial function in HIV-infected persons: randomised controlled trial. Heart. 2009;95(5):385\u201390.","journal-title":"Heart"},{"issue":"3","key":"132_CR28","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1097\/EDE.0000000000000041","volume":"25","author":"ES Brouwer","year":"2014","unstructured":"Brouwer ES, Napravnik S, Eron Jr JJ, et al. Effects of combination antiretroviral therapies on the risk of myocardial infarction among HIV patients. Epidemiology. 2014;25(3):406\u201317.","journal-title":"Epidemiology"},{"issue":"3","key":"132_CR29","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/QAI.0b013e31821d33a5","volume":"57","author":"M Durand","year":"2011","unstructured":"Durand M, Sheehy O, Baril JG, Lelorier J, Tremblay CL. Association between HIV infection, antiretroviral therapy, and risk of acute myocardial infarction: a cohort and nested case\u2013control study using Quebec\u2019s public health insurance database. J Acquir Immun Defic Syndr. 2011;57(3):245\u201353.","journal-title":"J Acquir Immun Defic Syndr"},{"issue":"3","key":"132_CR30","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/QAD.0b013e32835b2ef1","volume":"27","author":"A Monforte","year":"2013","unstructured":"Monforte A, Reiss P, Ryom L, et al. Atazanavir is not associated with an increased risk of cardio or cerebrovascular disease events. AIDS. 2013;27(3):407\u201315.","journal-title":"AIDS"},{"issue":"18","key":"132_CR31","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1097\/QAD.0b013e328340a21f","volume":"24","author":"L de Saint-Martin","year":"2010","unstructured":"de Saint-Martin L, Bressollette L, Perfezou P, et al. Impact of atazanavir-based HAART regimen on the carotid intima-media thickness of HIV-infected persons: a comparative prospective cohort. AIDS. 2010;24(18):2797\u2013801.","journal-title":"AIDS"},{"issue":"1","key":"132_CR32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1310\/hct1001-1","volume":"10","author":"A Hill","year":"2009","unstructured":"Hill A, Sawyer W, Gazzard B. Effects of first-line use of nucleoside analogues, efavirenz, and ritonavir-boosted protease inhibitors on lipid levels. HIV Clin Trials. 2009;10(1):1\u201312.","journal-title":"HIV Clin Trials"},{"key":"132_CR33","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ijcme.2014.08.006","volume":"5","author":"YSS Tatami","year":"2015","unstructured":"Tatami YSS, Ishii H, Shibata Y, Osugi N, Ota T, et al. Impact of serum bilirubin levels on carotid atherosclerosis in patients with coronary artery disease. IJC Metab Endocr. 2015;5:24\u20137.","journal-title":"IJC Metab Endocr"},{"issue":"3","key":"132_CR34","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3109\/07853890.2014.895588","volume":"46","author":"SJ Kang","year":"2014","unstructured":"Kang SJ, Lee C, Kruzliak P. Effects of serum bilirubin on atherosclerotic processes. Ann Med. 2014;46(3):138\u201347.","journal-title":"Ann Med"},{"issue":"2","key":"132_CR35","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0021-9150(01)00601-3","volume":"160","author":"L Vitek","year":"2002","unstructured":"Vitek L, Jirsa M, Brodanova M, et al. Gilbert syndrome and ischemic heart disease: a protective effect of elevated bilirubin levels. Atherosclerosis. 2002;160(2):449\u201356.","journal-title":"Atherosclerosis"},{"issue":"10","key":"132_CR36","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1111\/jgh.12279","volume":"28","author":"LJ Horsfall","year":"2013","unstructured":"Horsfall LJ, Nazareth I, Pereira SP, Petersen I. Gilbert\u2019s syndrome and the risk of death: A population-based cohort study. J Gastroenterol Hepatol. 2013;28(10):1643\u20137.","journal-title":"J Gastroenterol Hepatol"},{"key":"132_CR37","doi-asserted-by":"crossref","unstructured":"Perlstein TS, Pande RL, Creager MA, Weuve J, Beckman JA. Serum total bilirubin level, prevalent stroke, and stroke outcomes: NHANES 1999\u20132004. Am J Med. 2008;121(9):781\u20138 e781.","DOI":"10.1016\/j.amjmed.2008.03.045"},{"issue":"14","key":"132_CR38","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1161\/CIRCULATIONAHA.106.633206","volume":"114","author":"JP Lin","year":"2006","unstructured":"Lin JP, O\u2019Donnell CJ, Schwaiger JP, et al. Association between the UGT1A1*28 allele, bilirubin levels, and coronary heart disease in the Framingham Heart Study. Circulation. 2006;114(14):1476\u201381.","journal-title":"Circulation"},{"issue":"4 Suppl 3","key":"132_CR39","doi-asserted-by":"crossref","first-page":"19544","DOI":"10.7448\/IAS.17.4.19544","volume":"17","author":"V Estrada","year":"2014","unstructured":"Estrada V, Monge S, Gomez-Garre D, et al. Comparison of oxidative stress markers in HIV-infected patients on efavirenz or atazanavir\/ritonavir-based therapy. J Int AIDS Soc. 2014;17(4 Suppl 3):19544.","journal-title":"J Int AIDS Soc"},{"issue":"4","key":"132_CR40","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1097\/QAD.0000000000000970","volume":"30","author":"D Chow","year":"2016","unstructured":"Chow D, Kohorn L, Souza S, et al. Atazanavir use and carotid intima media thickness progression in HIV: potential influence of bilirubin. AIDS. 2016;30(4):672\u20134.","journal-title":"AIDS"},{"issue":"3","key":"132_CR41","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/cid\/civ316","volume":"61","author":"M Desai","year":"2015","unstructured":"Desai M, Joyce V, Bendavid E, et al. Risk of cardiovascular events associated with current exposure to HIV antiretroviral therapies in a US veteran population. Clin Infect Dis. 2015;61(3):445\u201352.","journal-title":"Clin Infect Dis"},{"key":"132_CR42","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1186\/s12879-016-1735-4","volume":"16","author":"CM Diaz","year":"2016","unstructured":"Diaz CM, Segura ER, Luz PM, et al. Traditional and HIV-specific risk factors for cardiovascular morbidity and mortality among HIV-infected adults in Brazil: a retrospective cohort study. BMC Infect Dis. 2016;16:376.","journal-title":"BMC Infect Dis"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-016-0132-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,9]],"date-time":"2022-07-09T06:51:56Z","timestamp":1657349516000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40121-016-0132-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,27]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["132"],"URL":"https:\/\/doi.org\/10.1007\/s40121-016-0132-z","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,27]]}}}